Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Stock Has Average Price Target of $29.00 According to Analysts

Key Points

• Analyst sentiment is moderately positive: Eight analysts give Kestra Medical Technologies a consensus “Moderate Buy” rating, with five buys, two holds, and one sell. The average 12-month price target is $29.00, while individual targets range as high as $34.00.
• KMTS shares were trading near their 12-month high at $29.42, up 2.3%, compared with a range of $17.34 to $30.00. The stock’s 50-day and 200-day moving averages were $26.51 and $23.73, respectively.
• Financial results and insider activity remain concerns: The company reported a quarterly loss of $0.75 per share, missing estimates by $0.14, alongside a negative net margin of 140.43%. Insiders sold 361,928 shares worth approximately $9.16 million over the past 90 days.

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $29.00.

Several equities analysts have recently commented on the stock. Wall Street Zen cut shares of Kestra Medical Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, September 12th. Royal Bank Of Canada set a $30.00 price target on Kestra Medical Technologies in a research note on Tuesday, September 15th. Evercore started coverage on Kestra Medical Technologies in a research note on Tuesday, October 20th. They set an "outperform" rating and a $34.00 price objective on the stock. Oppenheimer initiated coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a "market perform" rating on the stock. Finally, JPMorgan Chase & Co. started coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They issued an "overweight" rating and a $30.00 target price for the company.

Insider Buying and Selling at Kestra Medical Technologies

In other Kestra Medical Technologies news, Director Jeffrey Schwartz sold 3,890 shares of Kestra Medical Technologies stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $25.18, for a total value of $97,950.20. Following the completion of the transaction, the director owned 7,019 shares of the company's stock, valued at $176,738.42. The trade was a 35.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction on Tuesday, October 20th. The stock was sold at an average price of $29.56, for a total transaction of $443,400.00. Following the completion of the transaction, the insider directly owned 445,215 shares of the company's stock, valued at approximately $13,160,555.40. This represents a 3.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 361,928 shares of company stock worth $9,158,873. 5.30% of the stock is owned by insiders.

Institutional Trading of Kestra Medical Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. Sterling Capital Management LLC boosted its holdings in shares of Kestra Medical Technologies by 834.0% in the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock valued at $25,000 after buying an additional 784 shares during the period. Quantinno Capital Management LP acquired a new stake in Kestra Medical Technologies during the first quarter worth about $431,000. California State Teachers Retirement System raised its stake in Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock worth $555,000 after acquiring an additional 7,844 shares during the period. Spartan Wealth Advisory Services LLC bought a new position in Kestra Medical Technologies in the first quarter worth about $603,000. Finally, Bank of New York Mellon Corp lifted its holdings in Kestra Medical Technologies by 47.2% in the first quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company's stock worth $1,397,000 after acquiring an additional 22,471 shares during the last quarter.

Kestra Medical Technologies Trading Up 2.3%

KMTS opened at $29.42 on Tuesday. Kestra Medical Technologies has a 12-month low of $17.34 and a 12-month high of $30.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The stock has a market capitalization of $1.75 billion, a PE ratio of -11.02 and a beta of 0.51. The firm's fifty day moving average price is $26.51 and its 200 day moving average price is $23.73.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The company had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. As a group, research analysts expect that Kestra Medical Technologies will post -2.45 EPS for the current fiscal year.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.

The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.